| BIOA |
BioAge Labs, Inc. |
85%
|
Reciprocal relationship from BIOA graph: royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three m… |
| GLUE |
Monte Rosa Therapeutics, Inc. |
85%
|
Reciprocal relationship from GLUE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GLUE graph: pany has identified certain performance obligations within the agreement as… |
| RGNX |
REGENXBIO Inc. |
85%
|
Reciprocal relationship from RGNX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from RGNX graph: . (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Nova… |
| ANL |
Adlai Nortye Ltd. |
72%
|
Reciprocal relationship from ANL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ANL graph: asing by US$5 million as a result of advanced payments from customer. Investi… |
| ARE |
Alexandria Real Estate Equities, Inc. |
72%
|
Reciprocal relationship from ARE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARE graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARE gr… |
| ARGX |
argenx SE |
72%
|
Reciprocal relationship from ARGX graph: lement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more ful… |
| ARWR |
Arrowhead Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from ARWR graph: Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $132.7 million and $101.9 million for the three and six months ended March 31, 2026, compared to … |
| BNBX |
BNB Plus Corp. |
72%
|
Reciprocal relationship from BNBX graph: t our ability to maintain production of our products and achieve profitability. Unforeseen discontinuation or unavailability of certain components, such as en… |
| COLL |
Collegium Pharmaceutical, Inc. |
72%
|
Reciprocal relationship from COLL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from COLL graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from COLL… |
| CPMV |
Mosaic ImmunoEngineering, Inc. |
72%
|
Reciprocal relationship from CPMV graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CPMV graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CPMV… |
| CRNX |
Crinetics Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from CRNX graph: products in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement … |
| CTMX |
CytomX Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX… |
| CTNM |
Contineum Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTNM… |
| CYTK |
Cytokinetics, Incorporated |
72%
|
Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| ELVN |
Enliven Therapeutics, Inc. |
72%
|
Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ELVN… |
| GKOS |
Glaukos Corporation |
72%
|
Reciprocal relationship from GKOS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GKOS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from GKOS… |
| GLTO |
Damora Therapeutics, Inc. |
72%
|
Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses … |
| HLN |
Haleon plc |
72%
|
Reciprocal relationship from HLN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from HLN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from HLN gr… |
| IMNM |
Immunome, Inc. |
72%
|
Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with… |
| INCY |
Incyte Corporation |
72%
|
Reciprocal relationship from INCY graph: (in thousands): December 31, 2024 2023 Raw materials $ 27,590 $ 23,282 API and Work-in-process 331,178 209,793 Finished goods 48,431 36,862 Total inventory $ … |
| IRIX |
IRIDEX Corporation |
72%
|
Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| JBIO |
Jade Biosciences, Inc. |
72%
|
Reciprocal relationship from JBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from JBIO graph: fluctuate significantly from quarter to quarter and year to year. We antici… |
| KLRS |
Kalaris Therapeutics, Inc. |
72%
|
Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There ar… |
| KMDA |
Kamada Ltd. |
72%
|
Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA… |
| KYMR |
Kymera Therapeutics, Inc. |
72%
|
Reciprocal relationship from KYMR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KYMR… |
| LEGN |
Legend Biotech Corporation |
72%
|
Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LEGN… |
| LNTH |
Lantheus Holdings, Inc. |
72%
|
Reciprocal relationship from LNTH graph: ncreasingly competitive environment in which other PSMA PET imaging agents have been approved, for which discounts related to those other agents have been off… |
| LQDA |
Liquidia Corporation |
72%
|
Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from LQDA… |
| MLTX |
MoonLake Immunotherapeutics |
72%
|
Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MLTX… |
| MREO |
Mereo BioPharma Group plc |
72%
|
Reciprocal relationship from MREO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO… |
